400 completed, 50 terminated, 46 recruiting, 35 unknown. 579 Phase 1, 97 Phase 2.
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents - Alzheimer Disease, Early Onset | Phase 1 | Not yet recruiting | Columbia University | 6 | 2027-08-01 | 2026-05-13 |
| Repurposing a Combination Antiretroviral Drug Therapy to Target Retrotransposons and Treat Early Alzheimer's Disease Emtricitabine and tenofovir disoproxil fumarate combination, Placebo - Alzheimer's Disease | Phase 1 | Not yet recruiting | Brigham and Women's Hospital | 20 | 2026-12-01 | 2026-08-31 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults PF-08161842, Placebo for PF-08161842 - Alzheimer Disease | Phase 1 | Not yet recruiting | Pfizer | 98 | 2026-11-17 | 2026-10-30 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants SHR 3201 Injection, SHR 3201 Placebo. - Alzheimer's Disease | Phase 1 | Not yet recruiting | Beijing Suncadia Pharmaceuticals Co., Ltd | 50 | 2026-11-01 | 2026-10-26 |
| A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE) FMD1 (LNT22-017-1), Rapamycin, Placebo - Cerebral Blood Flow, APOE 4 | Phase 1 / Phase 2 | Not yet recruiting | Cedars-Sinai Medical Center | 60 | 2026-11-01 | 2026-09-16 |
| The Gut - PRO Study Probiotic, Placebo - Alzheimer Disease | Phase 1 | Recruiting | University of Wisconsin, Madison | 40 | 2026-11-01 | 2026-10-30 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD) E2511, Donepezil - Alzheimers Disease | Phase 1 | Not yet recruiting | Eisai Inc. | 32 | 2026-10-15 | 2026-08-17 |
| Escalating Doses of Memantine in Down Syndrome (MEDS-123) Memantine - Down Syndrome, Intellectual Disability | Phase 1 | Not yet recruiting | University Hospitals Cleveland Medical Center | 25 | 2026-10-14 | 2026-10-05 |
| A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD) LY4560736, Placebo, Florbetapir F18 - Healthy Volunteers, Alzheimer Disease | Phase 1 | Not yet recruiting | Eli Lilly and Company | 111 | 2026-10-01 | 2026-10-08 |
| DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau DUVAX 200 µg, DUVAX 400 µg, Placebo (Adjuvant only) - Alzheimer Disease, Alzheimer Disease (AD) | Phase 1 | Recruiting | Nuravax, Inc. | 24 | 2026-09-25 | 2026-09-30 |
| Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients 8M2D, Placebo - Alzheimer's Disease (AD) | Phase 1 | Not yet recruiting | Cenna Biosciences Inc. | 54 | 2026-09-15 | 2026-05-05 |
| A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease LY4405094, Placebo, Florbetapir F18 - Alzheimer Disease, Amyloid | Phase 1 | Recruiting | Eli Lilly and Company | 179 | 2026-09-09 | 2026-10-08 |
| Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo - Alzheimer Dementia (AD) | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 30 | 2026-09-01 | 2026-09-23 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-09-01 | 2026-10-07 |
| 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients 2-hydroxybenzylamine acetate, Placebo - Alzheimer Disease, Mild Cognitive Impairment | Phase 1 / Phase 2 | Not yet recruiting | MTI Biotech Inc | 48 | 2026-09-01 | 2026-09-24 |
| Repeat Intracerebroventricular Injections of RB-ADSC in Subjects Previously Treated in RBI Protocol RB-ADSC-02 RB-ADSC - Alzheimer Disease | Phase 1 | Not yet recruiting | Regeneration Biomedical, Inc. | 9 | 2026-09-01 | 2026-08-26 |
| A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration BMS-986446 - Alzheimer's Disease, Healthy Participants | Phase 1 | Recruiting | Bristol-Myers Squibb | 84 | 2026-08-21 | 2026-09-24 |
| A Study of GSM-779690T in Healthy Adult Participants GSM-779690T, Placebo - Healthy Adult Participants, Alzheimer Disease | Phase 1 | Not yet recruiting | Acta Pharmaceuticals | 72 | 2026-08-15 | 2026-07-09 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease DNL921, Placebo - Alzheimer's Disease, Healthy Participants | Phase 1 | Recruiting | Denali Therapeutics Inc. | 178 | 2026-08-07 | 2026-08-20 |
| Low-Dose Radiotherapy for Alzheimer's Disease Low Dose Radiation Therapy - Alzheimer Dementia, Dementia | Phase 1 / Phase 2 | Recruiting | Evan Thomas | 50 | 2026-07-15 | 2026-07-09 |
Showing 20 of 579. Sign in to see all of them.
Alzheimer Disease (558) · Cognitive Dysfunction (57) · Dementia (54) · Supranuclear Palsy, Progressive (22) · Parkinson Disease (19) · Neurodegenerative Diseases (15) · Plaque, Amyloid (13) · Central Nervous System Diseases (12) · Brain Diseases (10) · Huntington Disease (10) · Pick Disease of the Brain (10) · Memory Disorders (7) · Inflammation (6) · Multiple Sclerosis (6)
Nervous System Diseases (573) · Brain Diseases (568) · Central Nervous System Diseases (566) · Neurodegenerative Diseases (564) · Mental Disorders (558) · Neurocognitive Disorders (556) · Dementia (508) · Cognition Disorders (65) · Pathological Conditions, Signs and Symptoms (65) · Basal Ganglia Diseases (48) · Movement Disorders (48) · Neurologic Manifestations (39) · Signs and Symptoms (37) · Cranial Nerve Diseases (22)
Donepezil (27) · florbetapir (15) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (12) · BMS 708163 (10) · SAM-531 (9) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (8) · atabecestat (8) · latrepirdine (8) · 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (6) · Iodine-123 (5) · ispronicline (5) · ponezumab (5) · Caffeine (4) · Itraconazole (4) · Magnetic Resonance Spectroscopy (4)
Wyeth is now a wholly owned subsidiary of Pfizer (28) · Pfizer (23) · Eli Lilly and Company (21) · Merck Sharp & Dohme LLC (18) · Institute for Neurodegenerative Disorders (15) · GlaxoSmithKline (14) · AstraZeneca (12) · Avid Radiopharmaceuticals (12) · Bristol-Myers Squibb (12) · Biogen (8) · Eisai Inc. (8) · Janssen Research & Development, LLC (8) · AbbVie (7) · Cerecin (7) · Hoffmann-La Roche (7)
United States (341) · United Kingdom (39) · Sweden (31) · Australia (29) · Japan (29) · Netherlands (23) · South Korea (23) · China (22) · France (22) · Germany (20) · Spain (13) · Belgium (12) · Canada (12) · Austria (9) · Finland (9)
Danna Jennings, MD (11) · Danna L Jennings, MD (7) · Adam Boxer, MD, PhD (4)
PMID 37996817, PMID 25789616, PMID 26925577, PMID 27955995, PMID 29063518, PMID 30052328, PMID 30134967, PMID 30355322, PMID 31710340, PMID 34521461, PMID 39390616, PMID 39422960, PMID 40009460, PMID 40368603, PMID 41220869, PMID 15852017, PMID 17951067, PMID 18204357, PMID 18580589, PMID 19198615, PMID 19320056, PMID 19420314, PMID 20679141, PMID 21358740, PMID 21723605, PMID 22172392, PMID 22252372, PMID 22381714, PMID 22409311, PMID 22431837, PMID 22655593, PMID 22666474, PMID 22677258, PMID 22766391, PMID 22986776, PMID 23076723, PMID 23152610, PMID 23300829, PMID 24068826, PMID 24077434, PMID 24131736, PMID 24195007, PMID 24260218, PMID 24438512, PMID 24716469, PMID 24970906, PMID 25404952, PMID 25478017, PMID 25874001, PMID 26014587
2014 (5), 2023 (5), 2016 (4), 2015 (3), 2017 (3), 2019 (3), 2025 (3), 2009 (2), 2018 (2), 1RF1AG051514 (1), 1RF1AG058067-01A1 (1), 1UF1AG046148 (1), 1UH2TR000967-01 (1), 2008 (1), K08MH094441 (1)